Kovar A - Search Results

1

Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

Dirks NL, Nolting A, Kovar A, Meibohm B. Dirks NL, et al. Among authors: kovar a. J Clin Pharmacol. 2008 Mar;48(3):267-78. doi: 10.1177/0091270007313393. Epub 2008 Jan 24. J Clin Pharmacol. 2008. PMID: 18218786

2

The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

Gupta M, Kovar A, Meibohm B. Gupta M, et al. Among authors: kovar a. J Clin Pharmacol. 2005 Sep;45(9):987-1003. doi: 10.1177/0091270005276847. J Clin Pharmacol. 2005. PMID: 16100293 Review.

3

Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Budha NR, Kovar A, Meibohm B. Budha NR, et al. Among authors: kovar a. AAPS J. 2011 Dec;13(4):650-61. doi: 10.1208/s12248-011-9302-9. Epub 2011 Oct 18. AAPS J. 2011. PMID: 22005901 Free PMC article.

4

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.

Delbaldo C, Pierga JY, Dieras V, Faivre S, Laurence V, Vedovato JC, Bonnay M, Mueser M, Nolting A, Kovar A, Raymond E. Delbaldo C, et al. Among authors: kovar a. Eur J Cancer. 2005 Aug;41(12):1739-45. doi: 10.1016/j.ejca.2005.04.029. Eur J Cancer. 2005. PMID: 16051481 Clinical Trial.

5

The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.

Mehrotra N, Gupta M, Kovar A, Meibohm B. Mehrotra N, et al. Among authors: kovar a. Int J Impot Res. 2007 May-Jun;19(3):253-64. doi: 10.1038/sj.ijir.3901522. Epub 2006 Sep 21. Int J Impot Res. 2007. PMID: 16988721 Review.

6

Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis.

Dalla Costa T, Nolting A, Kovar A, Derendorf H. Dalla Costa T, et al. Among authors: kovar a. J Antimicrob Chemother. 1998 Dec;42(6):769-78. doi: 10.1093/jac/42.6.769. J Antimicrob Chemother. 1998. PMID: 10052901

7

[Microdialysis for the determination of free drugs in tissues].

Kovar A, Nolting A, Derendorf H. Kovar A, et al. Pharm Unserer Zeit. 1997 Jan;26(1):17-23. doi: 10.1002/pauz.19970260108. Pharm Unserer Zeit. 1997. PMID: 9157461 Review. German. No abstract available.

8

Changes in blood pressure after administration of hydroxocobalamin: relationship to changes in plasma cobalamins-(III) concentrations in healthy volunteers.

Uhl W, Nolting A, Gallemann D, Hecht S, Kovar A. Uhl W, et al. Among authors: kovar a. Clin Toxicol (Phila). 2008 Jul;46(6):551-9; discussion 576-7. doi: 10.1080/15563650701829763. Clin Toxicol (Phila). 2008. PMID: 18584369 Clinical Trial.

9

Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study.

Uhl W, Nolting A, Golor G, Rost KL, Kovar A. Uhl W, et al. Among authors: kovar a. Clin Toxicol (Phila). 2006;44 Suppl 1:17-28. doi: 10.1080/15563650600811755. Clin Toxicol (Phila). 2006. PMID: 16990190 Clinical Trial.

10

Population pharmacokinetics of cilengitide in adult and pediatric cancer patients from a nonlinear mixed-effects analysis.

Zühlsdorf M, Bhattaram VA, Campioni M, Krösser S, Derendorf H, Kovar A. Zühlsdorf M, et al. Among authors: kovar a. J Clin Pharmacol. 2014 Dec;54(12):1391-9. doi: 10.1002/jcph.343. Epub 2014 Jun 26. J Clin Pharmacol. 2014. PMID: 24911832 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters